Description
IntroductionI. Overview of Hallucinogens1. The Pharmacology of Psychedelics, David E. Nichols & Charles D. Nichols2. Plants for the People: The Future of Psychedelic Therapies in the Age of Biomedicine, Dennis J. McKenna3. Anthropology, Shamanism, and Hallucinogens, Michael Winkelman4. A Short, Strange Trip: LSD Politics, Publicity, and Mythology—from Discovery to Criminalization, Maria Mangini5. History of the Use of Hallucinogens in Psychiatric Treatment, Torsten PassieII. Neuroscience of Hallucinogens6. Human Neuroimaging Studies of Serotonergic Psychedelics, Enzo Tagliazucchi7. Memory Reconsolidation in Psycholytic Psychotherapy, Jim GrigsbyIII. Individual Hallucinogens8. Lysergic Acid Diethylamide (LSD), Kristine Panik & David Presti9. Psilocybin, Stephen Ross, Silvia Franco, Collin Reif, & Gabrielle Agin-Liebes10. Therapeutic Potential of Fast-Acting Synthetic Tryptamines, Rafael Lancelotta & Alan K. Davis11. Mescaline (3,4,5-trimethoxy-phenethylamine), Will Van Derveer12. MDMA, Michael Mithoefer & Annie Mithoefer13. Therapeutic and Social Uses of MDMA, Scott Shannon, Rob Colbert, & Shannon Hughes14. Biological and Psychological Mechanisms Underlying the Therapeutic Use of Ayahuasca, Dráulio Barros de Araújo, Luis Fernando Tófoli, Stevens Rehen, & Sidarta Ribeiro15. The Ibogaine Project: Urban Ethnomedicine for Opioid Use Disorder, Kenneth Alper16. Salvia Divinorum, Ana Elda Maqueda17. Ketamine, Gary Bravo, Robert Grant, & Raquel BennettIV. Therapeutic Considerations18. Set, Setting, and Dose, J. C. Callaway19. The Use of Music in Psychedelic Therapy, Mendel Kaelen20. The Role of the Guide in Psychedelic-Assisted Treatment, Mary Cosimano & Jim Grigsby21. Comparative Phenomenology and Neurobiology of Meditative and Psychedelic States of Consciousness: Implications for Psychedelic-Assisted Therapy, Milan Sheidegger22. Adverse Effects, Kelan Thomas and Benjamin MalcolmV. Indications and Purpose23. Utility of Psychedelics in the Treatment of Psychospiritual and Existential Distress in Palliative Care: A Promising Therapeutic Paradigm, Anthony P. Bossis24. Classic Psychedelics for Treatment of Alcohol Use Disorder, Michael P. Bogenschutz & Sarah E. Mennenga25. Psychedelics in the Treatment of Addiction, Matthew W. Johnson26. The Treatment of Depressive Disorders with Psychedelics, Dave King & Jonny Martell27. Hallucinogens in Headache, Emmanuelle A. D. SchindlerVI. Mystical/Religious Experiences and Philosophical Considerations28. Mystical/Religious Experiences with Psychedelics, William A. Richards29. Philosophical Considerations Concerning the Use of Hallucinogens in Psychiatric Treatment, Candice L. Shelby
Charles S. Grob, MD, is Professor of Psychiatry and Pediatrics at the David Geffin School of Medicine at the University of California, Los Angeles, and Director of the Division of Child and Adolescent Psychiatry at Harbor–UCLA Medical Center. He previously held faculty positions at the Johns Hopkins University and the University of California, Irvine. Dr. Grob has conducted approved clinical research with psychedelics since the early 1990s and has published numerous articles on psychedelics in the medical and psychiatric literatures, as well as several books. He is a founding board member of the Heffter Research Institute.Jim Grigsby, PhD, is Professor in the Department of Psychology and Professor in the Division of Health Care Policy and Research of the Department of Medicine at the University of Colorado Denver. His research and over 250 publications have focused primarily on neuropsychology, cognitive neuroscience, and health services. His work in neuroscience has included extensive research on executive functioning and on Fragile X-associated tremor/ataxia syndrome (FXTAS), of which he was a co-discoverer. Dr. Grigsby’s current research interests include the gut–brain axis and the therapeutic use of psilocybin and MDMA.